Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00no prior Q3 2019 on file Net Income-$5.96M-$5.96MN/M vs Q3 2019 EPS Diluted-$0.15-$0.15N/M vs Q3 2019 Operating Income-$5,963,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
ended Dec 31, 2019 · filed Feb 13, 2020 · 44 d after period end